MOTS-C

Current Legal Status (Mauritius)

MOTS-C was one of several peptides formally reviewed by FDA's Pharmacy Compounding Advisory Committee (PCAC) in July 2026, after being removed from the agency's restricted "Category 2" compounding list in April 2026. The committee voted to recommend MOTS-C for a possible compounding pathway under Section 503A — a non-binding recommendation, not FDA approval. Formal rulemaking was still in progress as this page was last updated, and even a finalized pathway would only apply to licensed compounding pharmacies dispensing under a physician's prescription, not direct-to-consumer retail sale.

Tiger Blood Pharmaceuticals is pursuing product registration in the Republic of Mauritius, where pharmaceutical products are regulated by the Pharmacy Board, operating under the Ministry of Health and Wellness pursuant to the Pharmacy Act 1983. MOTS-C is not currently registered as a pharmaceutical product in Mauritius, and our registration application has not yet been completed. Until registration is granted, MOTS-C is supplied strictly for laboratory research use and is not sold, marketed or labeled as a medicine, supplement or treatment for any condition in any jurisdiction.

Tiger Blood Pharmaceuticals does not hold regulatory approval for MOTS-C in the United States, the European Union, the United Kingdom, or any other jurisdiction. Because this website is publicly accessible, customers are responsible for confirming that the purchase, import and use of this product is lawful where they live before placing an order.

This page will be updated once our Mauritius registration status changes.